Lyell Immunopharma, Inc. LYEL
We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors. To achieve this, we are pioneering novel approaches designed to generate T‑cell therapies that drive long-lasting clinical responses. Our CAR T-cell product candidates start with the identification of promising cancer targets. We then engineer the patient's own living immune cells and arm them with our innovative enhancements, including CAR constructs, technologies and manufacturing protocols that are designed to endow T cells with more potent cancer cell killing capabilities.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M | $7.8M | $657.0K | — |
| R&D | — | — | $182.9M | $159.2M | $138.7M | $182.2M | $63.6M | — |
| SG&A | $45.1M | $52.0M | $67.0M | $117.3M | $89.1M | $46.9M | $39.2M | — |
| Total operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M | $219.7M | $102.7M | — |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M | -$211.9M | -$102.1M | — |
| Pre-tax income | -$274.4M | — | — | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M | -$204.5M | -$129.4M | — |
| EPS, basic | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 | — |
| EPS, diluted | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 | — |
| Shares, diluted (wtd. avg.) | 17.1M | 13.1M | 12.5M | 247.1M | 135.9M | 13.3M | 5,429 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $60.2M | $105.6M | $145.6M | $123.8M | $294.3M | $140.9M | $98.5M | $130.3M |
| Short-term investments | $187.0M | $264.9M | $400.6M | $516.6M | $321.0M | $472.2M | — | — |
| Total current assets | $260.9M | $379.6M | $554.7M | $651.3M | $626.3M | $617.5M | — | — |
| Property, plant and equipment | $34.8M | $48.2M | $102.7M | $123.0M | $120.1M | $77.0M | — | — |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.13B | $908.3M | — | — |
| Accounts payable | $2.9M | $5.4M | $4.8M | $3.9M | $3.2M | $9.4M | — | — |
| Total current liabilities | $49.4M | $53.8M | $34.5M | $37.0M | $46.7M | $49.3M | — | — |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M | $189.8M | — | — |
| Retained earnings | -$1.62B | -$1.35B | -$1.00B | -$767.5M | -$584.4M | -$334.1M | — | — |
| Total equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M | -$292.5M | -$111.1M | $850.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M | -$160.9M | $39.5M | — |
| Depreciation and amortisation | $11.5M | $19.6M | $20.2M | $18.0M | $13.6M | $4.3M | $1.3M | — |
| Stock-based compensation | $41.8M | $33.1M | $47.1M | $81.9M | $62.2M | $33.3M | $15.7M | — |
| Capital expenditure | $780.0K | $464.0K | $2.7M | $24.3M | $65.5M | $51.5M | $16.0M | — |
| Investing cash flow | $54.1M | $122.4M | $184.0M | -$11.5M | -$121.6M | -$273.5M | -$422.4M | — |
| Financing cash flow | $50.4M | $1.3M | $1.7M | $10.6M | $401.2M | $476.8M | $351.2M | — |
| Buybacks | — | — | — | $0 | $0 | $11.8M | $185.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016686.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $657.0K | $7.8M | $10.7M | $84.7M | $130.0K | $61.0K | $36.0K |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$129.4M | -$204.5M | -$250.2M | -$183.1M | -$234.6M | -$343.0M | -$274.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |